Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas




descargar 0.53 Mb.
títuloInmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas
página9/10
fecha de publicación20.01.2016
tamaño0.53 Mb.
tipoDocumentos
b.se-todo.com > Documentos > Documentos
1   2   3   4   5   6   7   8   9   10

Otras web de interés

European Centre for Allergy Research Foundation www.ecarf.org

GEMA (Guía Española para el Manejo del Asma) www.gemasma.com

GINA (Global Initiative for Asthma) www.ginasthma.com


110 BIBLIOGRAFÍA
. Alvarez Cuesta E., Boquete M, Cadahia A, Carrillo T, Fernandez L, Hernández J, Muñoz D. Normativa sobre Inmunoterapia en Enfermedades Alérgicas. Sociedad Española de aergología e Inmunología Clínica. 1990.


2. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases .Allergy 1998; 53 Suppl 44


3. Guardia P. en: Inmunoterapia como herramienta clínica moderna. Módulo 6: Inmunoterapia basada en la evidencia.. www.cursoinmunoterapia.com


4. Noon L. Prophylactic inoculation for hay fever. Lancet (1911). 1572- 3


5. K Aas, Standardization of allergen extracts. Dev Biol Stand (1975). 29: 341. 


6. Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Regulatory control and Standardization of allergenic extracts. Seventh International Paul-Ehrlich Seminar. September 7-10, 1993. Langen, Germany. R Kurth and D. Haustein editors. Gustav Fisher Verlag. Stuttgart. New York, 1994. pp155-61


7. Ishizaka K, Ishizaka T. Identification of gamma-E antibodies as a carrier of reaginic activity.. J Immunol. 1967. 99:1187-98.


8. Van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O,  Villalba M, Durham S, Becker SM, Aalbers M, André C, Barber D, Cistero Bahima A, Custovic A, Didierlaurent A, Dolman C, Dorpema JW, Di Felice G, Eberhardt F, Fernandez Caldas E, Fernandez Rivas M, Fiebig M, Focke M, Fötisch M, Gadermaier G, Das RG, Gonzalez Mancebo E, Himly M, Kinaciyan T, Knulst AC, Kroon AM, Lepp U, Marco FM, Mari A, Moingeon P, Monsalve R, Neubauer A, Notten S, Ooievaar-de Heer P, Pauli G, Pini C, Purohit A, Quiralte J, Rak S, Raulf-Heimsoth M, San Miguel Moncin MM, Simpson B, Tsay A, Vailes L, Wallner M, Weber B , The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification.  Allergy 2008; 63: 310–26

9. www.aemps.es Ficha técnica Grazax


10. www.pei.de Pharmnet- Oralair 

11. Radauer C, Breiteneder H. Pollen allergens are restricted to few protein families and show distinct patterns of species distribution. J Allergy Clin Immunol 2006;117:141-7.


12. Mothes N, Heinzkill M, Drachenberg KJ. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvant vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by blocking antibodies. Clin Exp Allergy 2003; 33:1198–208


13. Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy grasspollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract inallergic patients. Int Arch Allergy Immunol 2004; 135:44–53].


14. Moreno C, Fdez-Tavora L, Acero S, Alonso MD, Barasona MJ, Blanco R, Cisteró A, Conde J, Fernandez J, Fernandez S, Fdez-Rivas M, García BE, Garcia-Rodriguez R, Camacho E, Glez-Quevedo T, Gonzalo A, Guardia P, Sanchez-Cano M, Tabar AI, de la Torre F. Tolerance of a cluster schedule on the treatment of seasonal respiratory disease with pollen extracts quantified in mass units. J Invest Allergol Clin Immunol 2003; 13:221-7.


15. Tabar AI, Fdez-Tavora L, Alonso R, Castillo R, Cisteró-Bahima A, de la Torre Morín F, Fernandez J, García-Figueroa BE, Fernández S, García-González JJ, García-Robaina JC, Moreno F, Lobatón P, Sanchez-Machin I, de la Torre Martínez F. Tolerance of a cluster Schedule with a house dust mite extract quantified in mass units: multicentre study. J Invest Clin Immunol 2004; 14: 193-7


16. Guardia P, Moreno C, Justicia JL, Conde J, Cimarra M, Díaz M, Guerra F, Martínez-Cócera C, Gonzalo-Garijo MA, Pérez-Calderón R, González-Quevedo T, Sánchez-Cano M, Vigaray J, Acero S, Blanco R, Martín S, de la Torre F. Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units. Allergol Immunopathol (Madr). 2004 Sep-Oct;32(5):271-7.

17. Rodriguez F, Boquete M, Ibáñez MD, de la Torre-Martínez F, Tabar AI. Once Daily Sublingual Immunotherapy without Updosing. A New Treatment Schedule Int Arch Allergy Immunol 2006; 140:321-326

18. Vacunas de alergia: Normativa legal (europea y española) que afecta a la fabricación de extractos alergénicos para inmunoterapia. www.vacunasalergia.es


19. Chapman MD., Ferreira F., Villalba M., Cromwell O., Bryan D., Becker WM., Fernandez-Rivas M., Durham S., Vieths S., Van Ree R.; CREATE consortium. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122 (5): 882-889


20. Guardia Martínez P; Llamas Huerta ME. En: Inmunoterapia. Guía práctica para médicos residentes de alergología. Ed. Masson 2003; cap 3, pag 17-21


21. HJ Malling. Ponencia “Situación de la Inmunoterapia específica en Europa” en el Simposiun Allergopharma “Inmunoterapia del siglo XXI”. Sympoisum SEAIC. Logroño. 2009.


22. Wüthrich B, Gumowski PL, Fäh J, Hürlimann A, Deluze C, André C, Fadel R, Carat F. Safety and efficacy of specific immunotherapy with standardized allegenic extracts adsorbed on aluminium hydroxide. J Investig Allergol Clin Immunol 2001; 11 (3): 149-56


23. Nagore E, Martínez-Escribano JA, Tato A, Sabater V, Vilata JJ. Subcutaneous nodules following treatment with aluminium-containing allergen extracts. Eur J Dermatol. 2001;11(2): 138-40.


24. Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 2000; 121 (4):261-9


25. Würtzen PA, Lund L, Lund G, Holm J, Millner A, Henmar H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int Arch Allergy Immunol 2007; 144 (4): 287-95


26. Casanovas M, Martin R, Jimenez C, Caballero R, Fernández-Caldas E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy 2007; 37 (3): 434-40


27. Bousquet J.Sublingual Immunotherapy:Validated!. Allergy 2006; 61 (supp 81): 6-31


28. Durham S, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with one-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-9


29. Ibañez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B, Bufe A. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007; 18: 516-22


30. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy. 2008 Jul;38(7):1074-88.


31. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007 Sep;120(3):707-13.


32. Allam JP, Novak N, Fuchs C, Asen S, Berge S, Appel T, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcɛRI expression. J Allergy Clin Immunol. 2003;112:141–148.


33. Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy grasspollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract inallergic patients. Int Arch Allergy Immunol 2004; 135:44–53].


34. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132: 13–24


35. Canonica GW, and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111; 437-448, 2003.


36. Brunet C, Bédart PM, Lavoie A, Jobin M, Hébert J. Allergic rhinitis to ragweed pollen II. Modulation of histamine-releasing factor production by specific Immunotherapy. J Allergy Clin Immunol. 1992; 89: 87-94


37. Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy. 2009; 64: 811-4


38. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.


39. Passalacqua G, Albano M, Riccio A el al. Clinical and immunologic effects of a rush sublingual immunotherapy to parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol. 1999; 104: 964-8.


40. Guerra F, Carracedo J, Solana-Lara R, Sánchez-Guijo P, Ramírez R. TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis alter culture with specific allergens. J Allergy Clin Immunol. 2001; 107: 647-653


41. Radulovic S. Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008; 121: 1.467-1.472

42


. Ozdemir C. An immunological overview of allergen specific immunotherapy –subcutaneous and sublingual routes. Ther Adv Respir Dis 2009; 3: 253-262


43. Burgler S, Ouaked N, Bassin C, Basinski TM, Mantel PY, Siegmund K, Schmidt-Weber CB. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009;123: 588-95, 595.e1-7


44. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, Betbeder D, Balazuc AM, Van Overtvelt L, Moingeon P Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells.. J Allergy Clin Immunol. 2008 Sep;122(3):603-9


45. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006: 61 (Suppl. 82): 1–20


46. Cox L. Co-editors: Li JT, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol 2007;120: S25-85.


48. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3: 331-3


49. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Committee for medicianl products for human use. EMEA. 2007 Doc.Ref.CHMP/EWP/18504/2006



50. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005; 60: 1459-70


51. Dreborg S, Frew A. EAACI Position Paper: Allergen standardization and skin tests. Allergy 1993; 48:49-54


52. www.allergome.org


53. Serrano P. Sensibilizacion a alérgenos minoritarios de Olea europaea como causa de reacciones sistémicas por inmunoterapia alergenoespecífica. Tesis Doctoral. Universidad de Córdoba. 2007


54. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C, Quiralte J, Lombardero M, Villalba M, Salcedo G, Rodríguez R. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy. 2008; 63:1550-7


55. Vailes L, Sridhara S, Cromwell O, Weber B, Breitenbach M, Chapman M,Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products J Allergy Clin Immunol 2001; 107:641-6.


56. Van Ree R. Indoor allergens: Relevance of major allergen measurements and standardization. J Allergy Clin Immunol 2007; 119:270-7 .


57. Chabre HGouyon BHuet ABoran-Bodo VNony EHrabina MFenaille FLautrette ABonvalet MMaillère BBordas-Le Floch VVan Overtvelt LJain KEzan EBatard T, Moingeon P. Molecular variability of group 1 and 5 grass pollen allergens between Poideae species: implications for immunotherapy. Clin Exp Allergy. 2010; 40: 505-19


58. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy. 2008; 38: 1400-8


59. Duffort O, Palomares O, Lombardero M, Villalba M, Barber D, Rodríguez R, Polo F. Variability of Ole e 9 allergen in olive pollen extracts: relevance of minor allergens in immunotherapy treatments. Int Arch Allergy Immunol. 2006; 140: 131-8.


60. Abramson MJ, Puy Mr, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir rit Care Med 1995;151:696-74 . Ia


61. Bousquet J ockey R, Mallin HJ et al. Allergen immunotherapy : therapeutic vaccines or allergic diseaes. Wol Healt Organization. American Academy of Allergy Asthma and Immunoloy. Ann Allergy Asthma Immunol 1998;81:401-5


62. Lockey RF. “ARIA”: Global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001:108:497-9



63. Ross RN, Nelson H, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an análisis. Clin Ther 2000:22:342-50. Ia


64. Ross RN, Nelson H, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersesnitivity: a meta-análisis. Clin Ther 2000:22:351-8. Ia


65. Ross RN, Nelson H, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-análisis of prospective, randomized, double-lind, placebo-controlled studies. Clin Ther 2000:22:329-41. Ia


66. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Sys Rev. 2003:CD001186. Ia


67. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001186. DOI: 10.1002/14651858.CD001186.pub2.


68. Lowell C, Ranklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N En J Med 1965;273:675-9. Ia


69. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthm,a: significant improvement of allergen-specific parameters of nonspecific bronchial hyperreactivity. Allergy 2001;56:301-6. Ib


70. Bonno M,Fujisawa T, Iguchi K et al. Mite-specific induction of interleukin-2 receptor on T lympjocites from children with mite-sensitive asthma: modified immune response with immunotherapy. J Allergy Clin Immunol 1996;97:680-8. IIa


71. Hunt KJ, Valentine MD, Sootka AK, Benton AW Aodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity . N Eng J Med 1987;299:157-61. IIa


72. Cantani A, Arcese , Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective stuy o specific immunotherapy to inhalant allergens:evidence of safety and efficacy in 300 children with alllergic asthma. J Invest allergol Clin Immunol 1997;7:90-7. IIa


73. Ariano R, Kroon AM, Augeri G, Canonica W, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999. Ib


74. Durham Sr, Walter SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999;341:468-75. Ib


75. Horst M, Hejjaoui A, Horst V et al. Double-blind placebo controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-72. IIa


76. Nanda A, O’Connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized car allergen extract. J Allergy Clin Immunol 2004;114:1339-44. Ib


77. Fernández-Távora L, Rico P, Martín S. Clinical experience with specific immunotherapy to horse dander. J Investig Allergol Clin Immunol. 2002; 12: 29-33. III



78. Aas K. Hyposensitization in house dust allery asthma. A double blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand 1971;60:264-8. Ib


79. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach astma. J of Asthma 1988:25:205-18. Ib


80. Frew AJ, powell RJ, Corrigan CJ, Dirham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25. Ib


81. Corrigan CJ, Kettner J, Doemer , Cromwell O, Narkus A. Efficacy and safety of preseasonal –specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-7. Ib


82. Ferrer M, Burches E, Pealez A et al. Double-blind-placebo controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. j Investig Allergol lin Immunol 2005; 15.283-92. Ib


83. Jutel M, Jaeger l, Suck R, Meyer H, iebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-13. Ib


84. Portnoy JM. Immunotherapy for asthma: unfavourable studies. Ann Allergy Asthma Immunol 2001;87 (suppl 1):28-32


85. Adkinson N Jr, Egleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic childre. N Enl J Me 1997;36:324-31


86. Nigemann , Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study. specific immunotherapy and long-term prevention of asthma in children.j Allergy Clin Immunol 2006;855-9 III


87. Di Rienzo V, Marcucci F. Long-lasting effect of SLIT in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33: 206-10.


88. Des Roches A, Paradis L , Menardo JL, Boues S, Daures JP, Bousquet J. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. I. Specific immunotherapy prevents the onset of new sensitizations in children J Allergy Clin Immunol 1997;99:450-3. III


89. Pajno GB, Barberio G, De Luca F, Morabito L et al. Prevention of new sensnitizations in astmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 200131:1392-7. IIa


90. Jacobsen L, Valovirta e. How strong is the evidence that immunotherapy in children prevents te progresión of allergy and asthma? Curr opin Allergy Clin Immunol 2007;7:56-60. Ia


91. Wilson DR, Lima MT, urham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141-8. Ia


92. Garcia-Marcos L, Lucas Moreno JM, Garde JG. Sublingual immunotherapy. state of the art. Inflam Allergy rug Tarets. 2007:6-117-26


93. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Allergy Clin Immunol 2005; 15: 9-16.


94. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis:systematic rewiew and meta-analysis. Allergy 2005; 60: 4-12.


95. Calamita MA. Efficacy of sublinfual immunotherapy in asthma:systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61: 1162-72


96. Martin Penagos MD, Enrico Compalati, MD, Francesco Tarantini et al. Efficacy of sublingual in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006; 97: 141-148


97. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133(3):599-609


98. Compalati E, Passalacqua M, Bonini M, Canonica W. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GALEN meta-analysis. Allergy 2009, 64:1570-1579

99. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses.. J Allergy Clin Immunol. 2009 Jul;124(1):157-161.e1-32. Epub 2009 Jun 4.


100. Nelson HS, Lar J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extracts. J Allergy Clin Immunol 1997; 99:744-51. IIa


101. Enrique E, Pineda F, Malek et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind placebo controlled study with a standardized hazelnut extraxt. J Allergy Clin Immunol 2005;116:1073-9. Ib


102. Fernández-Rivas M, Garrido Fernández S, Nadal JA, Díaz de Durana MD, García BE, González-Mancebo E, Martín S, Barber D, Rico P, Tabar AI. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009 Jun;64(6):876-83. Epub 2009 Jan 21


103. A.D. Buchanan, T.D.G. Stacie, M. Jones, AM. Scurlock, L.Cristie, KA. Althage, RN, P H. Steele, L Pons, R M. Helm, L A. Lee, A. W Burks. Egg oral immunotherapy in nonanaphylactic children with egg allergy J Allergy Clin Immunol 2007;119:199-205.


104. Werfel T, Breuer K, Rueff R, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre , randomized, dose-response study. Allergy 2006;61:202-5. Ib


105. Glover MT, Aherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-6. Ib


106. Bussmann C, Bockenhoff A, Henke H et al. Does allergen-specific immunotherapy represents a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol2006;118.1292-8


107. Bucher X, Pihler WJ, Dahinden CA, Helbling A. effect of tree pollen specific subcutaneous immunotherapy on the oral allery síndrome to apple and hazelnut. Allergy 2004,59.1271-6. IIa


108. Hansen KS, Khinchi MS, Skov PS et al. Food allergy to apple and specific immunotherapy with birh pollen. Mol Nutr Food Res 2004;8:441-8. Ib


109. Bousquet J, Calvayrac P, Guerin B et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. In vivo and In vitro parametersafter a short course of treatment. J Allergy Clin Immunol 1985; 76:734-44. Ib


110. Durham SR, Varney V, Gaga M, rew Aj, Jacobson M, Kay AB. Immunotherapy and allergic infamation. Clin Exp Allergy 1991;21 (suppl 1): 206-10.


111. Till S. Immunotherapy: readdressing the balance between Th2 and Th1 cells. Clin Exp Allergy 1997,27:981-85


112. Ebner C. Immunological mechanisms operative in allergen-specific immunotherapya. Int Arch Allergy Immunol 1999;119 (1): 1-5


113. Varney VA, Edwards J, Tabbah K et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo –controlled trial. Cin Exp Allergy 1997;27:860-7. Ib

114


. Kohno Y, Minouchi K, Oda N et al. Effect of rhus immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998;102:927-34. IIa


115. Nieto A. en: Inmunoterapia como herramienta clínica moderna. Módulo 4: El seguimiento. www.cursoinmunoterapia.com


116. Malling HJ. Immunotherapy. EAACI Position paper. Allergy 1988 suppl 6. Vol 43


117. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48: 450-3


118. Moreno C, Cuesta-Herranz J, Fdez-Tavora L, Alvarez-Cuesta E. On behalf of the SEAIC. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004. 34: 527 – 31


119. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C, Quiralte J, Lombardero M, Villalba M, Salcedo G, Rodríguez R. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy. 2008; 63:1550-7


120. Barber D, Moreno C, Ledesma A, Serrano P, Galán A, Villalba M, Guerra F, Lombardero M, Rodríguez R. Degree of olive pollen exposure and sensitization patterns. Clinical implications. J Investig Allergol Clin Immunol. 2007; 17 Suppl 1: 11-6


121 . Barber D., Polo F., Lombardero M., Villalba M., Rodriguez R. The importance of minor allergens in allergen standardization. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006; (95): 128-134


122. Fdez-Tavora L, Garcia D. Inmunoterapia cluster con extractos de pólenes: estudios de tolerancia, cambios inmunológicos y eficacia clínica. Rev Esp Alergol Inmunol Clin 1991; 6: 68-74


123. Garcia Ortega P, Merlo A, Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergy asthma. Chest 1993; 103: 183-7


124. Moreno C, Guerra F. Inmunoterapia con veneno de himenópteros. Seguridad de una pauta agrupada. Alergol Immunol Clin 1999; 14: 315-21.


125. Moreno C, Fdez-Tavora L, Justicia JL, Cabeza N, Vidal C. Búsqueda de una pauta idónea para iniciación de inmunoterapia con un extracto de Alternaria tenuis. Alergol Immunol Clin 2001; 16: 133-7


126 . Moreno C, Fdez-Tavora L, Justicia JL, Cabeza N, Guerra F. Perfil asistencial de una pauta agrupada de inmunoterapia con extractos de polenes adsorbidos en hidróxido de aluminio. Alergol Inmunol Clin 2001; 16: 329-34


127. Guardia-Martínez P, Crespo-Moreira P, Conde-Alcañiz MA, et at. Safety of alternaria alternata cluster immunotherapy with standardized depot extrac. EAACI Annual Meeting. Amsterdam 2004. Abstract book


128. Sánchez-Machín I, Moreno C, González R, Iglesias-Souto J, Pérez E, Matheu V Safety of a 2-Visit Cluster Schedule of Venom Immunotherapy in Outpatients at Risk of Lifethreatening Anaphylaxis J Investig Allergol Clin Immunol 2010; 20: 91-2


129. Tabar A.I. Ferrer A, García I, Cimarra M. Seguridad de la inmunoterapia. Tratado de Alergología SEAIC. Cap 19; 355.


130. Antico A, Pagani M, Crema A, Anaphilaxis by látex sublingual immunotherapy. Allergy 2006; 1236-7.

131. Cistero Bahima A, Sastre J, Enrique E et al. Tolerante and effects on skin reactivity to latex sublingual rush immunotherapy with latex extract. L Invest Allergol Clin Immunol 2004; 14: 17-25.


132. Dunsky EH, Goldstein MF. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61: 1235.


133. Eifan AO, Keles S, Bahceciler NN et al. Anaphylaxis to multiple pollen allegen sublingual immunotherapy. Allergy 2007; 62: 567-8.


134. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Inmunoterapia con inyección de alérgenos para la rinitis alérgica estacional (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 4, 2007. Oxford, Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).


135. S. L. Delancy, W. V. Filley, C. E. Aston, J. R. Claflin . Systemic Reactions (SR) to Immunotherapy (IT) Using Standardized Extract in Over 700,000 Injections. J ALLERGY CLIN IMMUNOL Abstracts S77, VOLUME 117, NUMBER 2.


136. Moreno C. Optimising immunotherapy in pollinosis. 1st International Congress SEAS. 2010.


137. Roumana A, Pitsios C. The safety of initiating Hymenoptera immunotherapy at 1 mg of venom extract. J Allergy Clin Immunol 2009; 124: 379


138. Biller H, Badorrek P, Hohlfeld JM, Sager A, Krug N. Efficacy of a Rush Immunotherapy with a Depigmented Polymerized Extract of Grass Pollen assessed in an Environmental Challenge Chamber EAACI Congress 2009.


139. Serrano P, Justicia JL, Sánchez C, Cimarra M, Fernández-Távora L, Orovitg A, Moreno C, Guerra F, Alva V. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity–standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol. 2009; 102: 247–52.


140. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts.. Clinical and Experimental Allergy. 2007; 37: 434–40


141. Moreno C. Clustered immunotherapy for aeroallergens. EAACI Barcelona 2008. http://ejournals.ebsco.com/direct.asp


142. Serrano P, J. Algorta J, Martínez A, González-Quevedo T, Velázquez E. Díaz M. Prospective safety study of immunotherapy administered in acluster Schedule. J Invest Allergol Clin Immunol 2004; 14: 312-19


143. Moreno C, Guerra F. Inmunoterapia con veneno de himenópteros. Seguridad de una pauta agrupada. Alergol Immunol Clin 1999; 14: 315-21.



144. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001 Jan; 107: 81-6.


145. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized placebo-controlled trial. J Allergy Clin Immunol 1997; 100: 458-63.


146. Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol. 2007; 144: 137-42.


147. Soriano Gomis VGonzalez Delgado PNiveiro Hernandez E.Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol. 2008; 18: 225-6.


148. Galera CSoohun NZankar NCaimmi SGallen CDemoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009; 19: 225-9.


149. De Luque V., Guardia P., Alcaraz C., López C., Nogales MD.; Conde J., Tolerability of despigmentado polimerised extract. Abstract CD. 2010 Meeting. London.


150. De Luque V., Fernández-Távora L., Guardia P. Seguridad y eficacia de pauta agrupada intraestacional con Allergovit(R). Comunicación I Reunión Allergopharma. Sevilla, 7 octubre 2010.


151. Barasona MJ. Tesis. Universidad de Córdoba DEBE DARME MAS DATOS

152. Cavallucci ERamondo SRenzetti ATuri MCDi Claudio FBraga MIncorvaia CSchiavone CBallone EDi Gioacchino M Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence. J Investig Allergol Clin Immunol. 2010; 20: 63-8.


153. Moreno C, Barasona MJ, Serrano P, Justicia JL, Ruz JM, Guerra F. Alternant Polistes-Vespula venom immunotherapy: A therapeutic strategy to solve a diagnostic deficiency. Enviado para publicación


154. Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, Aldunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005; 116: 109-18.


155. Tankersley MS, Butler KK, Butler VK, Goetz DW. Local reaction during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106: 840-3.

156. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol 1990;86:407-11. III


157 Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005;22:272-3. IV


159. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990 Feb;85(2):473-9

160. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol 2004;135:332-5.

1   2   3   4   5   6   7   8   9   10

similar:

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconLas técnicas de manipulación del adn están en estado incipiente,...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconDel griego klima, clima y therapeia, tratamiento. Aplicación, a la...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconResumen el tratamiento de la Pseudoartrosis Congénita de Tibia y...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconPlegamiento y agregación errónea de las proteínas y su relación con las enfermedades

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconLas enfermedades crónicas adquieren el carácter de “enfermedad social”...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEs del último grupo de enfermedades genéticas. Estas enfermedades...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEnfermedades en Ciudad Juárez, México y el mundo y programas gubernamentales...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconReacciones alérgicas fatales

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEl mayor problema a través de la historia de la humanidad, con relación...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconResumen Las enfermedades ampollosas autoinmunes (eaa) comprenden...




Todos los derechos reservados. Copyright © 2019
contactos
b.se-todo.com